Recent data reveals that prescriptions for medications used to treat Attention Deficit Hyperactivity Disorder (ADHD) in England have surged by 18% year-on-year since the Covid-19 pandemic.

Experts attribute this increase, documented by researchers from Aston University and the University of Huddersfield, to a combination of heightened awareness of ADHD, particularly through social media platforms such as TikTok and Instagram, and the pandemic's influence on mental health.

The study highlights that ADHD prescriptions rose from 25.17 items per 1,000 people in the 2019-2020 period to 41.55 items in the 2023-2024 period.

The medications examined include three stimulants—methylphenidate (brand names such as Ritalin, Concerta, and Delmosart), dexamfetamine, and lisdexamfetamine—along with two non-stimulants, atomoxetine and guanfacine.

Among the medicines, methylphenidate continues to be the most widely prescribed, while lisdexamfetamine has experienced the highest annual growth rate at 55%.

The rise in prescriptions has been observed uniformly across all seven regions of England, with increases varying from 13% in the North East and Yorkshire region to 28% in London.

The South East of England reported an annual increase of 19.37%.

Experts noted that the documented increase in ADHD prescriptions corresponds with a growing body of evidence that supports the effectiveness of these medications in enhancing quality of life and reducing substance misuse among diagnosed individuals.

Additionally, they emphasized that medications play a critical role, particularly when alternative treatment options, such as psychological or behavioral therapies, are limited.

The surge in awareness surrounding ADHD, driven significantly by social media interactions, has reportedly encouraged more individuals to seek diagnoses and treatment options.

Thousands have shared personal experiences and coping strategies related to ADHD on platforms like TikTok and Instagram, contributing to the dialogue around the condition.

Despite the positive aspects of increased awareness, researchers raised concerns regarding the potential spread of misinformation on these platforms, which could perpetuate misunderstandings about ADHD symptoms, diagnosis, and treatment.

They called for further investigation into the need for moderating and vetting ADHD-related information disseminated through social media to mitigate the potential consequences of inaccurate or misleading content.

The Covid-19 pandemic has notably altered daily routines and increased stress levels for many, factors that researchers assert may have exacerbated ADHD symptoms in some individuals.

Consequently, this could have led to an uptick in diagnostic assessments and treatment in response to more pronounced symptoms.

Current estimates suggest that approximately 5% of children and 3-4% of adults in the UK are diagnosed with ADHD, but the recent data indicates a possible ongoing rise in these figures.

ADHD is characterized by symptoms such as inattention, hyperactivity, and impulsivity, which can interfere with day-to-day activities.

Key figures in mental health, such as Dr. Ulrich Muller-Sedgwick from the Royal College of Psychiatrists, have acknowledged the recent influx of individuals seeking support for ADHD, attributing it to various factors including heightened awareness and the pandemic’s impact on mental health.

Additionally, Dr. Paul Keedwell, a consultant psychiatrist specializing in neurodiversity, has stated that the rates of ADHD diagnoses among children and adolescents have remained stable between 2020 and 2023, but increased significantly for adults mainly due to better awareness, reduced stigma, and greater accessibility to assessments, particularly in the private sector.

He highlighted the necessity for thorough evaluations to avoid misdiagnosis, as other mental health conditions can often present symptoms similar to ADHD.